For pharmaceutical and biotech drug developers, increased drug complexity and stricter requirements are pushing companies to find new and innovative ways to package their drug products. From the discovery phase through commercial launch, choosing the right packaging solution could be the determining factor in the success of your project. As two long-term industry players, Datwyler and SCHOTT have developed a new packaging solution, ideal for the complexities faced during drug development: the Starter Pack.
On average, the development of a new medicine takes 10 to 15 years and costs around $2.6 billion. Drug development involves comprehensive clinical trial phases, of which less than 12 percent of the candidate medicines make it into phase I, where clinical trials are eventually approved by the authorities. Driven by the latest developments in the field of medicine, such as, cell & gene therapy, tissue engineering, and regenerative medicine, the complexity is expected to increase even further in the future. Considering all critical aspects within drug development, Datwyler and SCHOTT developed the Starter Pack, which provides a range of compatible primary packaging components to be used in every drug development application – from drug discovery to drug delivery. The Starter Pack is designed to provide customers with a complete, robust, ready-to-use packaging system, easy to order and ready to be globally delivered in small quantities. The combination of The combination of Datwyler Omni Flex stoppers, Prime Caps, and SCHOTT adaptiQ® vials provides an ideal sealing solution which prevents leaks and other seal integrity concerns throughout manufacturing and handling.